Literature DB >> 20722787

Pulse pressure independently predicts major cardiovascular events in younger but not in older subjects with erectile dysfunction.

Giovanni Corona1, Matteo Monami, Valentina Boddi, Giulia Rastrelli, Cecilia Melani, Daniela Balzi, Alessandra Sforza, Gianni Forti, Edoardo Mannucci, Mario Maggi.   

Abstract

INTRODUCTION: Pulse pressure (PP; i.e., the arithmetic difference between systolic and diastolic blood pressure) has been suggested to be an independent cardiovascular risk (CV) factor in the general population. We previously also reported a negative association between PP and arteriogenic erectile dysfunction (ED). This finding has recently been questioned. AIM: To verify the association of PP with ED severity and to evaluate its role in predicting forthcoming CV events.
METHODS: This is an observational prospective cohort study evaluating a consecutive series of 1,687 patients attending our Andrological Unit for ED. MAIN OUTCOME MEASURES: Several hormonal and biochemical parameters were studied, along with SIEDY structured interviews and penile Doppler ultrasound.
RESULTS: Subjects with PP in the lowest quartile (I: 20-45; II: 46-55; III: 56-62; IV: 63-115 mm Hg) had a significant reduction in the risk of severe ED (RR = 0.60[0.47-0.76]; P < 0.0001). When the same analysis was repeated as a function of age quartile (I = 17-44, II = 45-55, III = 56-62, and IV = 63-88 years old), after adjusting for testosterone levels, mean blood pressure, Chronic Disease Score, and body mass index, PP was inversely related to ED only in the youngest age group. During a mean follow up of 4.4 ± 2.6 years, 147 major cardiovascular events (MACE) were observed. In a Cox regression model, after adjusting for possible confounding factors, a lower PP was associated with a lower risk of MACE in the whole sample and in younger subjects, but not in the older ones.
CONCLUSIONS: Checking for blood pressure in ED subjects and calculating PP should become a routine practice in sexual medicine. In younger individuals, low PP reflects not only sexual health (better erection) but also cardiovascular health (less prevalence of MACE).
© 2010 International Society for Sexual Medicine.

Entities:  

Mesh:

Year:  2010        PMID: 20722787     DOI: 10.1111/j.1743-6109.2010.01966.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  6 in total

Review 1.  Sex Hormones and Sex Chromosomes Cause Sex Differences in the Development of Cardiovascular Diseases.

Authors:  Arthur P Arnold; Lisa A Cassis; Mansoureh Eghbali; Karen Reue; Kathryn Sandberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03-09       Impact factor: 8.311

2.  The correlation between high sensitivity C-reactive protein and erectile dysfunction patients with hypertension treated with vardenafil.

Authors:  S Azab; H Aoud; N Nabil
Journal:  Int J Impot Res       Date:  2016-12-01       Impact factor: 2.896

Review 3.  Erectile dysfunction and central obesity: an Italian perspective.

Authors:  Giovanni Corona; Giulia Rastrelli; Sandra Filippi; Linda Vignozzi; Edoardo Mannucci; Mario Maggi
Journal:  Asian J Androl       Date:  2014 Jul-Aug       Impact factor: 3.285

Review 4.  Biomarkers, erectile dysfunction, and cardiovascular risk prediction: the latest of an evolving concept.

Authors:  Charalambos Vlachopoulos; Nikolaos Ioakeimidis; Christodoulos Stefanadis
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

Review 5.  Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs.

Authors:  Dimitrios Terentes-Printzios; Nikolaos Ioakeimidis; Konstantinos Rokkas; Charalambos Vlachopoulos
Journal:  Nat Rev Cardiol       Date:  2021-07-30       Impact factor: 32.419

6.  The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil.

Authors:  Andrea M Isidori; Giovanni Corona; Antonio Aversa; Daniele Gianfrilli; Emmanuele A Jannini; Carlo Foresta; Mario Maggi; Andrea Lenzi
Journal:  Int J Endocrinol       Date:  2014-05-15       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.